Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a median lifespan of 2-3 years after diagnosis. There are few meaningful treatments that alter progression in this disease. Preclinical and clinical studies have demonstrated that neuroinflammation may play a key role in the progression rate of ALS. Despite this, there are no validated biomarkers of neuroinflammation for use in clinical practice or clinical trials. Biomarkers of neuroinflammation could improve patient management, provide new therapeutic targets, and possibly help stratify clinical trial selection and monitoring. However, attempts to identify a singular cause of neuroinflammation have not been successful. Here, we performed multi-parameter flow cyt...
Background: Amyotrophic lateral sclerosis (ALS) is a devastating and untreatable motor neuron diseas...
In order to test the hypothesis that the immune system plays a role in the pathogenesis of amyotroph...
OBJECTIVE: To evaluate the combined blood expression of neuromuscular and inflammatory biomarkers as...
Immunity has emerged as a key player in neurodegenerative diseases such as amyotrophic lateral scler...
Amyotrophic lateral sclerosis (ALS) is an idiopathic fatal neurodegenerative disease that is charact...
Aims: Neuroinflammation might be involved in the degeneration and progression of Amyotrophic Lateral...
Amyotrophic lateral sclerosis (ALS) is a rare but lethal neurodegenerative disease, characterized by...
BACKGROUND AND OBJECTIVES: Aging is known to exacerbate neuroinflammation, and in the neurodegenerat...
Despite wide genetic, environmental and clinical heterogeneity in amyotrophic lateral sclerosis, a r...
<p>Leukocyte phenotypes from HVs and ALS patients sub-grouped into Profiles 1 and 2 were compared. <...
Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative disease. D...
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease, characterized by the progressi...
Objective: To investigate inflammatory cytokines in patients with motor neuron disease (MND) evaluat...
Serum and CSF from 32 patients with idiopathic ALS, 30 agematched controls and 30 MS patients were i...
Background: Loss of neuroprotective role of CD4+ helper T cells, regulatory T cells, and M2 microgli...
Background: Amyotrophic lateral sclerosis (ALS) is a devastating and untreatable motor neuron diseas...
In order to test the hypothesis that the immune system plays a role in the pathogenesis of amyotroph...
OBJECTIVE: To evaluate the combined blood expression of neuromuscular and inflammatory biomarkers as...
Immunity has emerged as a key player in neurodegenerative diseases such as amyotrophic lateral scler...
Amyotrophic lateral sclerosis (ALS) is an idiopathic fatal neurodegenerative disease that is charact...
Aims: Neuroinflammation might be involved in the degeneration and progression of Amyotrophic Lateral...
Amyotrophic lateral sclerosis (ALS) is a rare but lethal neurodegenerative disease, characterized by...
BACKGROUND AND OBJECTIVES: Aging is known to exacerbate neuroinflammation, and in the neurodegenerat...
Despite wide genetic, environmental and clinical heterogeneity in amyotrophic lateral sclerosis, a r...
<p>Leukocyte phenotypes from HVs and ALS patients sub-grouped into Profiles 1 and 2 were compared. <...
Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative disease. D...
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease, characterized by the progressi...
Objective: To investigate inflammatory cytokines in patients with motor neuron disease (MND) evaluat...
Serum and CSF from 32 patients with idiopathic ALS, 30 agematched controls and 30 MS patients were i...
Background: Loss of neuroprotective role of CD4+ helper T cells, regulatory T cells, and M2 microgli...
Background: Amyotrophic lateral sclerosis (ALS) is a devastating and untreatable motor neuron diseas...
In order to test the hypothesis that the immune system plays a role in the pathogenesis of amyotroph...
OBJECTIVE: To evaluate the combined blood expression of neuromuscular and inflammatory biomarkers as...